BioSpace News Archive

Mind Medicine today announced that members of the Company’s management team will participate in Canaccord Genuity’s New Paradigms and Treatment Approaches in Mental Health Conference.

Tris Pharma, Inc. announced today that they have expanded their partnership whereby Pediatrix Therapeutics received exclusive rights to commercialize Tris’s entire FDA-approved ADHD portfolio as well as ADHD pipeline products in China.

Citius Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Biologics License Application (BLA) for denileukin diftitox (“I/ONTAK” or “E7777"), an engineered IL-2-diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL).

Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of the Rare Patient Network expanding Invitae’s Ciitizen platform to all patients with pediatric epilepsy and/or developmental delay with plans to include other conditions in the coming months.

Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pelareorep in combination with Roche’s anti-PD-L1 checkpoint inhibitor atezolizumab.

WISE Cortical Strip is the first cortical strip embedding the electrodes in a highly compliant thin film of silicone to receive FDA clearance.

Haystack Oncology today announced the appointment of Joel Kaufman as Chief Financial Officer.

Cidara Therapeutics, Inc. (NASDAQ: CDTX) today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 11,510,992, entitled Compositions and Methods for the Treatment of Viral Infections, for CD388, a highly potent, long-acting drug-Fc conjugate (DFC) designed to achieve universal prevention of seasonal and pandemic influenza.

Theriva Biologics announced that Company’s Management will participate in the following upcoming investor conferences in December.

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using targeted protein inhibition and targeted protein degradation to develop therapies for patients with cancer in need of new treatment options, announces interim clinical trial results from the company’s Phase 1/2 trial of its novel oral, reversible, targeted LSD1 inhibitor, seclidemstat, as a treatment for Ewing sarcoma and FET-rearranged sarcomas.